Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target (CROSBI ID 299248)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Božić, Joško ; Kumrić, Marko ; Tičinović Kurir, Tina ; Maleš, Ivan ; Borovac, Josip Anđelo ; Martinović, Dinko ; Vilović, Marino Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target // Biomedicines, 9 (2021), 10; 1407, 12. doi: 10.3390/biomedicines9101407

Podaci o odgovornosti

Božić, Joško ; Kumrić, Marko ; Tičinović Kurir, Tina ; Maleš, Ivan ; Borovac, Josip Anđelo ; Martinović, Dinko ; Vilović, Marino

engleski

Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target

Although a large amount of data supports the crucial role of endothelial dysfunction (ED) in cardiovascular diseases (CVDs), there is a large bench-to-bedside chasm between basic and clinical research of ED, limiting the implementation of these findings in everyday clinical settings. Hence, it is important to further investigate the pathophysiological mechanisms underlying ED and find modalities that will alleviate its clinical implementation. Adropin, a highly conserved peptide hormone secreted primarily by the liver, recently emerged as an important regulatory component of the vascular endothelium. Specifically, the vasoprotective role of adropin is achieved mainly by affecting endothelial NO synthesis. Thus, in this review, we aimed to summarize the current knowledge regarding the role of adropin in physiological processes and address the protective role of adropin in endothelium with consequent implications to CV pathologies. We focused on data regarding the role of adropin in the clinical setting, with concurrent implications to future clinical use of adropin. Studies suggest that plasma levels of adropin correlate with indices of ED in various pathologies and enhanced disease progression, implying that adropin may serve as a useful biomarker of ED in the upcoming future. On the other hand, despite notable results with respect to therapeutic potential of adropin in preliminary experiments, further well-designed studies are warranted in order to establish if adropin might be beneficial in this setting.

adropin ; endothelial dysfunction ; cardiovascular disease ; pathophysiology ; biomarkers

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

9 (10)

2021.

1407

12

objavljeno

2227-9059

10.3390/biomedicines9101407

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost